ReviewFrontiers in immunology2021

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma.

Qijun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.